Drug intelligence / Profile preview

SPYVLP04

Development stage: Preclinical
Lead developer: SpyBiotech
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Injection

Overview

SPYVLP04 is a preclinical virus-like particle (VLP) vaccine candidate being developed by SpyBiotech for the prevention of Epstein-Barr virus (EBV) infection. The vaccine is built using SpyBiotech's proprietary protein "superglue" technology (SpyTag/SpyCatcher), which allows for the stable and high-density display of EBV antigens on a VLP platform. This presentation is intended to trigger a potent immune response, potentially addressing the unmet need for a vaccine against EBV, a virus linked to infectious mononucleosis, multiple sclerosis, and several types of cancer.

Other names: SPYVLP

Targets

gL (Epstein-Barr virus glycoprotein L)

Beyond the preview

Go deeper on SPYVLP04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPYVLP04.

Explore the full profile